Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESTRO 2021 | Prevalence of severe side effects in the PACE-B trial

Alison Tree • 9 Sep 2021
ESTRO 2021
Genitourinary Cancer Prostate Cancer
PACE-B

Alison Tree, BSc, MBBS, FRCR, MD(res), The Royal Marsden NHS Foundation Trust, London, UK, discusses survivorship in the PACE-B trial (NCT01584258) comparing hypofractionated stereotactic body radiotherapy (SBRT) to conventional radiotherapy for treating men with localised prostate cancer. The trial results show that less than 1% of patients experienced severe side effects two years after treatment, regardless of which treatment group they were assigned. This interview took place at the European Society for Radiotherapy and Oncology (ESTRO) 2021.

More from Alison Tree

PACE-C: two-year toxicity outcomes with SBRT versus MHRT in prostate cancer
1:12
PACE-C: two-year toxicity outcomes with SBRT versus MHRT in prostate cancer
Alison Tree • 15 Dec 2025
2026 updates and upcoming trials in prostate cancer radiotherapy
1:41
2026 updates and upcoming trials in prostate cancer radiotherapy
Alison Tree • 15 Dec 2025
The benefits of shortened radiotherapy for prostate cancer
0:54
The benefits of shortened radiotherapy for prostate cancer
Alison Tree • 15 Dec 2025
PACE-B: 5 year updates of SBRT in localized prostate cancer
2:00
PACE-B: 5 year updates of SBRT in localized prostate cancer
Alison Tree • 15 Dec 2025

Related Videos

Real-world outcomes highlight unmet needs in R/R germ cell tumors
1:26
Real-world outcomes highlight unmet needs in R/R germ cell tumors
Darren Feldman • 24 Oct 2026
The future of targeting claudin-6 in relapsed germ cell tumors
0:52
The future of targeting claudin-6 in relapsed germ cell tumors
Darren Feldman • 24 Oct 2026
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
2:18
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
Darren Feldman • 24 Oct 2026
How will EIK1003 fit in the treatment landscape of prostate cancer?
0:42
How will EIK1003 fit in the treatment landscape of prostate cancer?
Guru Sonpavde • 24 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals